Webinar: Substance Abuse and Naltrexone at the Worksite

Over 107,000 Americans died from drug overdoses in 2023. Employers are aware of that incidence and that the threat of excessive or illicit opioid use among their workforce remains considerable. They are often, however, reluctant to take specific steps to mitigate the risk of an overdose event in the workplace. With the increased awareness and availability of opioid reversal agents such as naloxone, the opportunity has never been better to implement a thoughtful and protective plan. This session will detail important compliance and safety issues, and will provide an outline for program development.

Dr. Goldsmith is Founder and President of NBS Healthcare Group, a cooperative of healthcare professionals engaged in developing innovative solutions to today’s health and wellness challenges. Before moving to NBS Group, he served as Executive Director for Employee Health for Novartis Services, Inc., where his responsibilities included oversight of health services and clinical support for the Novartis Global Benefits Group. At Novartis he created an employer-sponsored, integrated healthcare delivery system for employees and their families. Prior to his employment with Novartis, he served as Associate Global Medical Director for the General Electric Company and had been in private internal medicine practice in his hometown of Stamford, Connecticut. Dr. Goldsmith received his medical degree from Albert Einstein College in New York, trained at Greenwich Hospital and the Yale-New Haven Medical Center and earned his Masters Degree in Public Health from the University of Connecticut. He is an assistant professor in the Department of Medicine at the Vagelos School of Medicine, Columbia University. In addition to his corporate career, Dr. Goldsmith is team physician for Stamford’s high school athletes and has published on occupational risk among marijuana users, innovations in primary prevention and exercise-induced asthma.